Dimerix Ltd (AU:DXB) — Market Cap & Net Worth
Market Cap & Net Worth: Dimerix Ltd (DXB)
Dimerix Ltd (AU:DXB) has a market capitalization of $72.22 Million (AU$102.07 Million) as of June 10, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20434 globally and #690 in its home market, demonstrating a -8.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dimerix Ltd's stock price AU$0.17 by its total outstanding shares 600396776 (600.40 Million). Review DXB liabilities breakdown to assess the company's total debt and financial obligations.
Dimerix Ltd Market Cap History: 2015 to 2026
Dimerix Ltd's market capitalization history from 2015 to 2026. Data shows growth from $55.65 Million to $72.22 Million (1.20% CAGR).
Dimerix Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dimerix Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
186.24x
Dimerix Ltd's market cap is 186.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $55.65 Million | $610.27K | -$5.25 Million | 91.19x | N/A |
| 2017 | $52.17 Million | $554.62K | -$1.76 Million | 94.06x | N/A |
| 2018 | $37.13 Million | $845.29K | -$3.32 Million | 43.92x | N/A |
| 2019 | $54.25 Million | $1.45 Million | -$2.89 Million | 37.49x | N/A |
| 2020 | $98.09 Million | $2.34 Million | -$4.49 Million | 41.90x | N/A |
| 2021 | $102.25 Million | $4.44 Million | -$6.37 Million | 23.03x | N/A |
| 2022 | $60.54 Million | $6.46 Million | -$10.49 Million | 9.37x | N/A |
| 2023 | $87.09 Million | $36.79K | -$13.80 Million | 2367.36x | N/A |
| 2024 | $144.44 Million | $583.48K | -$17.07 Million | 247.55x | N/A |
| 2025 | $233.65 Million | $1.25 Million | -$13.25 Million | 186.24x | N/A |
Competitor Companies of DXB by Market Capitalization
Companies near Dimerix Ltd in the global market cap rankings as of June 10, 2026.
Key companies related to Dimerix Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #225 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #431 globally with a market cap of $63.48 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #574 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #597 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #225 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $445.77 |
| #431 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.48 Billion | $616.18 |
| #574 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #597 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Dimerix Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Dimerix Ltd's market cap moved from $55.65 Million to $ 72.22 Million, with a yearly change of 1.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$72.22 Million | -69.09% |
| 2025 | AU$233.65 Million | +61.76% |
| 2024 | AU$144.44 Million | +65.85% |
| 2023 | AU$87.09 Million | +43.86% |
| 2022 | AU$60.54 Million | -40.80% |
| 2021 | AU$102.25 Million | +4.24% |
| 2020 | AU$98.09 Million | +80.81% |
| 2019 | AU$54.25 Million | +46.11% |
| 2018 | AU$37.13 Million | -28.83% |
| 2017 | AU$52.17 Million | -6.26% |
| 2016 | AU$55.65 Million | 0.00% |
| 2015 | AU$55.65 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 10th, 2026 the market cap of Dimerix Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.22 Million USD |
| MoneyControl | $72.22 Million USD |
| MarketWatch | $72.22 Million USD |
| marketcap.company | $72.22 Million USD |
| Reuters | $72.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more